11:44 AM EDT, 03/25/2026 (MT Newswires) -- Corcept Therapeutics' ( CORT ) Relacorilant in combination with nab-paclitaxel has been approved to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, the US Food and Drug Administration said Wednesday.

The approval is for patients who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab, the regulator said.

Shares of Corcept were up over 27% in midday trading.

Price: 43.05, Change: +9.23, Percent Change: +27.28